The pandemic within: tackling brain vulnerability in COVID19 at high resolution: NEUROCOV
- Funded by European Commission
- Total publications:4 publications
Grant number: 101057775
Grant search
Key facts
Disease
Severe Acute Respiratory Syndrome (SARS)Start & end year
20222027Known Financial Commitments (USD)
$8,384,036Funder
European CommissionPrincipal Investigator
SCHULTZE JoachimResearch Location
GermanyLead Research Institution
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EVResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare. Despite the towering success of vaccine development, lack of preparedness on integrative clinical and molecular phenotyping has emerged with clarity and highlights the need to scale translational efforts for personalized prevention and therapy. Of particular concern are the long-term consequences of SARS-CoV-2 infection with high and rising prevalence of chronic manifestations referred to as Post-COVID. Among these the neurological and psychiatric complications stand out for frequency, lack of treatment and devastating impact of their effects at pandemic scale. Here, we tackle the cognitive and neurodegenerative complications of COVID-19, referred to as NeuroCOVID, as a ticking pandemic within the pandemic that requires an innovation leap across disciplines. We pursue a multi scalar approach that reaches from epidemiology and mechanistic interrogation of host/virus interplay at single cell resolution through predictive modelling all the way to validation of biomarkers and repurposed drugs. The aim is to anticipate and effectively manage personalized trajectories of NeuroCOVID vulnerability and their impact at population level. For this we leverage two leading national health registries and three clinical cohorts to characterize the phenotypic spectrum of NeuroCOVID, its risk factors and its socioeconomic burden at high definition. We pioneer innovative robotics to scale brain organoid modelling and combine it with single cell multiOMICs and AI analytics to dissect the principles of the individual host response and render experimentally actionable the authentic genetic backgrounds of differential SARS-CoV-2 sensitivity. Through a substantive engagement of patients'Äô collectives and health care stakeholders, upstream integration of innovative pipelines streamlines translation and operationalizes precision medicine for emerging medical needs.
Publicationslinked via Europe PMC
Last Updated:43 minutes ago
View all publications at Europe PMC